相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Blood neurofilament light levels segregate treatment effects in multiple sclerosis
Benedicte Delcoigne et al.
NEUROLOGY (2020)
PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade
Qi Peng et al.
NATURE COMMUNICATIONS (2020)
Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis
Finn Sellebjerg et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Clinical and MRI correlates of CSF neurofilament light chain levels in relapsing and progressive MS
Alfredo Damasceno et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients
Jan W. Traub et al.
JOURNAL OF NEUROINFLAMMATION (2019)
Prognostic value of serum neurofilaments in patients with clinically isolated syndromes
Gloria Dalla Costa et al.
NEUROLOGY (2019)
Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod
Fredrik Piehl et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod
Fredrik Piehl et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment
Ulrike Buehler et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment
Ulrike Buehler et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Disrupted balance of T cells under natalizumab treatment in multiple sclerosis
Kimitoshi Kimura et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2016)
Natalizumab treatment leads to an increase in circulating CXCR3-expressing B cells
Maija Saraste et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2016)
Natalizumab in progressive MS Results of an open-label, phase 2A, proof-of-concept trial
Jeppe Romme Christensen et al.
NEUROLOGY (2014)
Effect of Natalizumab Treatment on Circulating Plasmacytoid Dendritic Cells: A Cross-Sectional Observational Study in Patients with Multiple Sclerosis
Pia Kivisaekk et al.
PLOS ONE (2014)
Axonal Damage in Relapsing Multiple Sclerosis is Markedly Reduced by Natalizumab
Martin Gunnarsson et al.
ANNALS OF NEUROLOGY (2011)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Plasmacytoid dendritic cells are increased in cerebrospinal fluid of untreated patients during multiple sclerosis relapse
Ana Leda F. Longhini et al.
JOURNAL OF NEUROINFLAMMATION (2011)
MHC class II-restricted antigen presentation by plasmacytoid dendritic cells inhibits T cell-mediated autoimmunity
Magali Irla et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Monoclonal antibodies in MS Mechanisms of action
Bibiana Bielekova et al.
NEUROLOGY (2010)
Plasmacytoid dendritic cells in multiple sclerosis:: Intracerebral recruitment and impaired maturation in response to interferon-β
Roberto Lande et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2008)
CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions
M. Krumbholz et al.
JOURNAL OF NEUROIMMUNOLOGY (2007)
Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings
E Fainardi et al.
JOURNAL OF NEUROIMMUNOLOGY (2003)
分享论文
